Physician profile
Zafar U Khalid
NPI 1689657975
$1,949.20
in general payments reported to CMS, 2019-2025
23 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $156 · 2021: $55.92 · 2022: $557 · 2023: $490 · 2024: $96.28 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $469.69 | 2022-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $425.75 | 2019-2023 | |
| Pfizer INC. | $202.39 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $166.62 | 2019-2025 | Airsupra, Farxiga |
| Inspire Medical Systems, INC. | $148.99 | 2023-2024 | Inspire |
| Amgen INC. | $83.94 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $76.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $50.08 | 2025 | |
| Boston Scientific Corporation | $49.58 | 2025 | Watchman Flx |
| Lilly USA, LLC | $46.27 | 2023-2024 | Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $26.27 | 2025 | Rezdiffra |
| Qol Medical, LLC | $24.48 | 2023 | Sucraid |
| Shield Therapeutics INC | $22.31 | 2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.85 | 2019 | |
| Abbvie INC. | $19.93 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $17.85 | 2021 | |
| Radius Health, INC. | $16.79 | 2025 | |
| Itamar Medical INC | $15.59 | 2022 | |
| Hikma Pharmaceuticals USA | $15.22 | 2019 | |
| Novo Nordisk INC | $13.96 | 2020 | |
| Chiesi USA, INC. | $13.08 | 2019 | |
| Allergan, INC. | $11.92 | 2019 | |
| Amarin Pharma, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zafar Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.